ATR Inhibition Synergizes With Alkylating PI Polyamide Targeting MYCN by Suppressing DNA Repair in MYCN‐Amplified Neuroblastoma
Open Access
- 7 March 2025
- journal article
- Published by Wiley in Cancer Science
- Vol. 116 (6) , 1691-1702
Abstract
Amplification of MYCN is a major oncogenic driver of high‐risk neuroblastomas. We previously developed CCC‐002, a MYCN‐selective pyrrole‐imidazole polyamide conjugated to a DNA alkylating agent. Administration of CCC‐002 to MYCN‐amplified (MYCN‐amp) neuroblastoma cells triggered the activation of DNA damage responses. Here, we demonstrated that among the DNA damage response inhibitors, ataxia telangiectasia and Rad3‐related (ATR) inhibitors synergized with CCC‐002 to suppress DNA repair‐related genes and induce apoptosis in MYCN‐amp neuroblastoma cells. A synergistic antitumor effect was verified in an SK‐N‐BE(2) xenograft mouse model, in which the combined use of CCC‐002 and ATR inhibitor at low doses significantly inhibited tumor progression. Notably, SK‐N‐BE(2) and SK‐N‐DZ cells, which showed ATM activation after CCC‐002 treatment, exhibited high sensitivity to the combined treatment of ATR inhibitors. Comprehensive analysis of the gene expression profiles revealed that the combination treatment upregulated apoptosis‐related pathways and downregulated DNA repair‐related pathways. After the combined treatment of CCC‐002 and ATR inhibitor, MYCN‐amp cells showed less FISH probe signal and mRNA expression of MYCN, which was accompanied by an increase in DNA damage markers in the genomic region of MYCN, highlighting that ATR inhibitors synergize with CCC‐002 and play a crucial role in the development of a novel MYCN‐targeting therapy for MYCN‐amp neuroblastoma.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP22zf0127001, JP23zf0127001)
- Takeda Science Foundation
- Japan Agency for Medical Research and Development (JP22ek0210168)
This publication has 42 references indexed in Scilit:
- Poly (ADP-ribose) polymerase inhibitor sensitized DNA damage caused by an alkylating pyrrole-imidazole polyamide targeting MYCN in neuroblastoma cellsBiochemical and Biophysical Research Communications, 2024
- RAD54B potentiates tumor growth and predicts poor prognosis of patients with luminal A breast cancerBiomedicine & Pharmacotherapy, 2019
- The comings and goings of PARP-1 in response to DNA damageDNA Repair, 2018
- A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancerLung Cancer, 2017
- PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastomaOncogene, 2017
- Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterationsCancer, 2015
- Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole–imidazole polyamide conjugateNature Communications, 2015
- Tumor Xenograft Uptake of a Pyrrole–Imidazole (Py-Im) Polyamide Varies as a Function of Cell Line GraftedJournal of Medicinal Chemistry, 2014
- HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 functionOncogene, 2007
- p63 and p73 are required for p53-dependent apoptosis in response to DNA damageNature, 2002